Artelo Biosciences, Inc. (ARTL) has risen to 52.32% in the premarket. However, the last trading session closed at $0.7156 with a decline of 3.21%.
Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
ARTL reported on 4th August 2021 that Medical Cannabis and Cannabinoids have published the study’s findings. The experiments were set up to investigate the in vitro effects of pure natural and synthetic forms of Cannabidiol (CBD) in human cell lines to see whether there were any pharmacological differences. Purified natural CBD has no antiproliferative, anti-inflammatory, or permeability properties in vitro, according to the research.
Moreover, proprietary cocrystal contains CBD and tetramethylpyrazine (TMP), both of which exhibit anti-cancer capabilities in vitro and in vivo. Both of these substances, however, have low oral bioavailability as individuals. CBD and TMP had synergistic and additive interactions when it came to preventing cancer cell development and killing cancer cells. As a result, experts believe that ART12.11 is a promising medication candidate with the potential to treat a wide range of diseases, including cancer, PTSD, inflammatory bowel disease, and others. Lastly, recently granted composition of matter patents might provide market exclusivity until 2038.
Third Quarter 2021 Results
ARTL reported third-quarter 2021 results on 12th July 2021. Operating costs were $2,251,412 as compared to $951,395 in the same period in 2020. Increased research and development operations, professional costs for continuing regulatory needs, and general and administrative expenditures, drove the Company’s operating expenses. Moreover, ART27.13 is a novel mechanism-based strategy to enhance appetite and weight gain recognized to arise from CB1 receptor activation. It was presented as a poster at the 31st Annual International Cannabinoid Research Society (ICRS) Symposium, with the potential to significantly benefit patients with cancer anorexia.
At ICRS, a paper was presented on Artelo’s ART12.11 CBD Cocrystal and its ability to limit cancer cell development and destroy cancer cells by combining CBD with TMP. In the CAReS research, the first patient was given ART27.13 for the treatment of cancer-related anorexia and weight loss. Positive laboratory evidence connected with unique CBD cocrystal has been released, suggesting that combining CBD and TMP can give ART12.11 a better pharmacodynamic profile than either CBD or TMP alone.
New Appointment to Board of Directors
ARTL announced on 4th May 2021 that Tamara A. Seymour is the new Senior Vice President of Business development. Ms. Seymour has three decades of expertise in corporate finance, including 20 years as a finance director in the biotech and life sciences sectors. Finance, corporate communications, planned care and reimbursement, human resource management, administrative, and information technology are just a few of the areas that she has led.
Moreover, she has generated more than $250 million in private and public equity and debt financings, as well as directed an initial public offering (IPO). As the company continues to advance the platform assets VAL-083 and REM-001, Tamara’s ideas and insights will be a significant addition to the Board and the whole Company. The company appreciates John’s contributions to the Board of Directors, and look forward to working with Tamara as the Company’s Senior Vice President of Business Development.
